KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $13.7 million.

  • Novavax's Net Cash Flow rose 11213.55% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.2 million, marking a year-over-year decrease of 26146.87%. This contributed to the annual value of -$30.8 million for FY2024, which is 9599.7% up from last year.
  • Latest data reveals that Novavax reported Net Cash Flow of $13.7 million as of Q3 2025, which was up 11213.55% from -$17.4 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Net Cash Flow registered a high of $1.4 billion during Q1 2021, and its lowest value of -$703.5 million during Q1 2023.
  • In the last 5 years, Novavax's Net Cash Flow had a median value of -$84.9 million in 2024 and averaged -$19.4 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 121482.23% in 2021, then crashed by 139019.42% in 2023.
  • Quarter analysis of 5 years shows Novavax's Net Cash Flow stood at -$419.5 million in 2021, then surged by 112.29% to $51.6 million in 2022, then tumbled by 265.77% to -$85.5 million in 2023, then skyrocketed by 61.84% to -$32.6 million in 2024, then skyrocketed by 142.05% to $13.7 million in 2025.
  • Its Net Cash Flow was $13.7 million in Q3 2025, compared to -$17.4 million in Q2 2025 and -$265.9 million in Q1 2025.